Navigation Links
Mylan Receives Approval for Generic Version of Zyban(R)
Date:5/4/2010

PITTSBURGH, May 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-release Tablets USP (SR), 150 mg, the generic version of GlaxoSmithKline's smoking cessation aid, Zyban®.  

Bupropion HCl ER Tablets had U.S. sales of approximately $9.7 million for the 12 months ending Dec. 31, 2009, according to IMS Health. The product is available for immediate shipment.

Currently, Mylan has 140 ANDAs pending FDA approval representing $96.5 billion in annual brand sales, according to IMS Health. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $19.6 billion in annual brand sales, for the 12 months ending Dec. 31, 2009, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Receives Approval for Generic Version of Flomax(R)
2. Mylan Schedules First Quarter 2010 Financial Results Conference Call and Live Webcast
3. Mylan Receives Approval for Generic Version of Actigall(R)
4. Mylan Awarded NABP-VAWD Accreditation for Its Primary North American Distribution Facility
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
11. Mylan Added to NASDAQ-100 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2017)... 10, 2017  Eli Lilly and Company (NYSE: ... 3 studies of galcanezumab, an investigational treatment for the ... on several key secondary endpoints for galcanezumab compared to ... studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today ... in Boston . ...
(Date:6/8/2017)...   Responding to Heath Ledger,s father,s recent ... singer Chris Cornell in May, the mental health ... free online psychiatric drug side effects search ... psychotropic drug risks. The father of the ... accidental overdose, has called for tighter rules on prescription drugs. ...
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance ... to communities in the greater Chicago metropolitan area, is embarking on a charity ... youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of ...
(Date:6/22/2017)... CA (PRWEB) , ... June 22, 2017 , ... Plastic ... named as a Top Doctor for 2017. Each year, research and information firm, Castle ... First winning the title in 2015, this marks the 3rd time that Dr. ...
(Date:6/22/2017)... ... June 22, 2017 , ... The VA Maryland Health ... Network has awarded the Baltimore VA Medical Center, a division of the VA ... its efforts to promote waste reduction and promote recycling. Also, Practice Greenhealth ...
(Date:6/20/2017)... ... June 20, 2017 , ... Connance, a leading ... will present how predictive analytics drive reimbursement optimization, with a focus on denial ... 25-28. , “The traditional approach to denied and underpaid claims leaves money ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Fresenius Vascular Care, ... minimally invasive techniques to treat and manage a wide range of vascular conditions, has ... initiative. With more than 65 centers represented by more than 40 local brands, a ...
Breaking Medicine News(10 mins):